Tempus AI Raises $410M in IPO, Sees Revenue Surge
Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
- Latest
- Trending
Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Researchers tested GPT-4's performance in diagnosing eye problems and found it outscored some expert ophthalmologists. GPT stands for "Generative Pre-trained ...
A majority of patients believe that when used properly, AI can enhance healthcare. However, many are wary of its increasing ...
GPT-4 shows promising potential in identifying stroke-affected brain regions, though it occasionally makes mistakes. Improving diagnosis speed could be beneficial, ...
The University of Kansas study found that AI responses are 70% shorter than those of real physicians but may have ...
Nalu Medical, a Carlsbad-based company, raised $20M in Series E funding for their innovative solutions in treating chronic neuropathic pain. ...
Cagent Vascular's series C financing round has raised over $30m, enabling them to expand their product portfolio and accelerate US ...
China Medical University Hospital (CMUH) is partnering with Google Cloud to use generative AI for cancer care. The AI can ...
Diversity in biotechnology and venture capital is crucial for driving innovation and breakthroughs in healthcare, according to Dr. Stanley Lewis. ...
Efforts to diversify biotech venture capital funding could lead to innovation, breakthroughs in healthcare, and improved outcomes for minorities.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.